secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0000929638-24-001513
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical reports 2023 net loss $26.2M; first FDA approval for Quelimmune pediatric device
--------------------------------------------------------------------------------

- Net loss $26.2M ($1.21/share) in 2023 vs $12.2M ($1.48/share) in 2022; cash $176K at Dec 31, 2023.
- FDA approved SCD-Pediatric (Quelimmune) in Feb 2024 for pediatric AKI with sepsis; distribution via Nuwellis.
- NEUTRALIZE-AKI adult trial enrolled 24 subjects; interim analysis expected H2 2024 after 100 reach 90-day endpoint.
- Appointed David A. Green as CFO in Jan 2024; completed $9.0M registered direct offering same month.
- Restated 2022 financials (non-cash items); minimal impact on cash/operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000092963824001513/0000929638-24-001513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000092963824001513/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-24-001513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer